Caplin Point Lab: It is engaged in the manufacturing & sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA & other countries.
🏅Forbes Asia's 200 Best Under A Billion 2021
@AvadhMaheshwar2 @kuttrapali26 #longterm
🧵..
🏅Forbes Asia's 200 Best Under A Billion 2021
@AvadhMaheshwar2 @kuttrapali26 #longterm
🧵..
2. History - Caplin Point was established in 1990. The company set out to manufacture a range of ointments, creams and external applications. The company was listed in 1994.Caplin Point deepened its presence in the emerging markets of West Africa, Latin America and the Caribbean.
3. Business - It has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 26 therapeutic segments.
🌟Revenue %
Latin America - 87%
USA - 8%
Africa - 5%
🌟Segment %
Generics - 75%
Branded Generics - 25%
🌟Revenue %
Latin America - 87%
USA - 8%
Africa - 5%
🌟Segment %
Generics - 75%
Branded Generics - 25%
4. Manufacturing Capabilities - The company has 8 manufacturing facilities in TN, Puducherry in India & in HKG, Colombia and SGP. Caplin is venturing on a Capex journey of INR ~300 cr. to widen its product portfolio and backward integrate majority of the products. #CAPEX
5. Research Capabilities- The company ranks #1 in India across industries for avg. R&D spend as a
% of revenue in the past 5 years.
👉The company has 5 dedicated R&D setups across India
👉Capex investment of over INR 1.6 bn over last 5 years towards enhanced manufacturing and R&D
% of revenue in the past 5 years.
👉The company has 5 dedicated R&D setups across India
👉Capex investment of over INR 1.6 bn over last 5 years towards enhanced manufacturing and R&D
6. KPI -
🌟Strength:
- Expansion to US market
- Best in class R&D capabilities
- Consistent Sales growth
- Investments in Caplin Steriles Ltd
- New Subsidiary for Oncology Specific Business
🔥Risk :
- Concentration risk (87% from Latin America)
- China dependency
#longterm
🌟Strength:
- Expansion to US market
- Best in class R&D capabilities
- Consistent Sales growth
- Investments in Caplin Steriles Ltd
- New Subsidiary for Oncology Specific Business
🔥Risk :
- Concentration risk (87% from Latin America)
- China dependency
#longterm
Loading suggestions...